These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15321889)

  • 1. Indian patients go to court over cancer drug.
    Murdur G
    BMJ; 2004 Aug; 329(7463):419. PubMed ID: 15321889
    [No Abstract]   [Full Text] [Related]  

  • 2. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
    Goldman J
    Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic myelogenous leukaemia market.
    Storey S
    Nat Rev Drug Discov; 2009 Jun; 8(6):447. PubMed ID: 19483705
    [No Abstract]   [Full Text] [Related]  

  • 4. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
    Kimura S; Kako S; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Watanabe T; Kanda Y
    Leuk Res; 2011 Jan; 35(1):e11-2. PubMed ID: 20952061
    [No Abstract]   [Full Text] [Related]  

  • 5. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 6. [Economic burden for patients with chronic myelogenous leukemia--healthcare economics and medical governance of cancer].
    Kodama Y; Kami M
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):577-81. PubMed ID: 20414010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicine. Shortages of cancer drugs put patients, trials at risk.
    Kaiser J
    Science; 2011 Apr; 332(6029):523. PubMed ID: 21527686
    [No Abstract]   [Full Text] [Related]  

  • 8. Increasing access to care for chronic myeloid leukemia patients: assessment of a scaling-up program.
    Ladner J; Tekinturhan E; Tavolacci MP; Audureau E; Saba J
    J Health Care Poor Underserved; 2013 Nov; 24(4):1486-97. PubMed ID: 24185146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is India ready to lead the battle for fair access to medicines?
    Lancet Oncology
    Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
    [No Abstract]   [Full Text] [Related]  

  • 10. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations.
    Gratwohl A; Baldomero H; Schwendener A; Gratwohl M; Urbano-Ispizua A; Frauendorfer K
    Leukemia; 2007 Mar; 21(3):383-6. PubMed ID: 17311065
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted cancer therapy: from bench to bedside to patient.
    Gellad WF
    J Clin Oncol; 2014 Feb; 32(4):268-70. PubMed ID: 24366939
    [No Abstract]   [Full Text] [Related]  

  • 12. [Novartis should discontinue its patent case in India!].
    PehrOlov P
    Lakartidningen; 2007 Feb 14-20; 104(7):524. PubMed ID: 17375688
    [No Abstract]   [Full Text] [Related]  

  • 13. Final hearings begin in epic legal battle over Novartis drug in India.
    Mudur G
    BMJ; 2012 Sep; 345():e6257. PubMed ID: 22991008
    [No Abstract]   [Full Text] [Related]  

  • 14. Gleevec (STI-571) for chronic myeloid leukemia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):49-50. PubMed ID: 11402258
    [No Abstract]   [Full Text] [Related]  

  • 15. The GLIVEC international patient assistance programme: the Nairobi experience.
    Kiarie GW; Othieno-Abinya NA; Riyat MS
    East Afr Med J; 2009 Dec; 86(12 Suppl):S106-7. PubMed ID: 21591520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate--a new oral targeted therapy.
    Savage DG; Antman KH
    N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
    [No Abstract]   [Full Text] [Related]  

  • 17. US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says.
    Cohen D
    BMJ; 2014 Nov; 349():g6593. PubMed ID: 25370846
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do affluent societies have the only options for the best therapy?
    Gajewski JL; Robinson P
    Leukemia; 2007 Mar; 21(3):387-8. PubMed ID: 17311066
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
    Chen Z; Wang C; Xu X; Feng W
    Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.